About New England Biolabs
New England Biolabs is a Healthcare company based in Ipswich (United Kingdom) founded in 1970 by Donald Comb. Molecular biology reagents company. The company has 50 employees. New England Biolabs has completed 1 acquisition, including Fluorogenics. Its chief executive, as recorded, is James Ellard. Its website neb.com draws about 749 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is N.E.B. LTD.
Company details
Founded in 1970, New England Biolabs operates in the molecular biology sector from Ipswich, United Kingdom. Discovery, development, and commercialization of reagents and kits are focused on genetic engineering, synthetic biology, and genomics. Over 200 recombinant and 30 native restriction enzymes, along with nicking enzymes and DNA methylases, form the core portfolio. Research and development in these areas are supported globally.
- Latest Funding Round$10.75K (USD), Grant
Jun 2018
- InvestorsHHS
& 3 more
- Employee Count50
- Investments & Acquisitions
Apps and channels of New England Biolabs
New England Biolabs publishes 1 mobile app.
Funding Insights of New England Biolabs
- Total Rounds 19
- Last Round Grant — $10,750
- First Round $2.53M
(Jun 1994)
- Investors Count 4
Latest 10 of 19 funding rounds of New England Biolabs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $10,750 | Grant | – | – | |
| Apr 2014 | $250,000 | Grant | – | – | |
| Jun 2013 | $2.07M | Grant | – | – | |
| Nov 2012 | $640,000 | Grant | – | – | |
| Jun 2012 | $960,499 | Grant | – | – | |
| Jun 2012 | $3.27M | Grant | – | – | |
| Mar 2012 | $919,556 | Grant | – | – | |
| Jun 2011 | $362,382 | Grant | – | – | |
| Mar 2011 | $1.26M | Grant | – | – | |
| Dec 2010 | $148,960 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in New England Biolabs
New England Biolabs has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Massachusetts Life Sciences Center and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences innovation is supported through funding and programs. | masslifesciences.com | Waltham, United States | ||
| sbir.nih.gov | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for New England Biolabs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of New England Biolabs
105 people are tracked at New England Biolabs (39 in leadership, 66 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Donald Comb | Founder & Chairman | Leadership |
James Ellard | CEO | Leadership |
Denisa Gilaj | Director Of Production | Leadership |
Joel Lackovich | Associate Director, US OEM & Customized Solutions Sales | Leadership |
Melanie Dibiasio | Executive Director Of Production | Leadership |
Mike Pelletier | Director Of Global Operations | Leadership |
Tara Morris | Director Of Executive Operations | Leadership |
Tom Evans | Executive Director of Research | Leadership |
Salvatore Russello | CEO | Leadership |
Richard Roberts | Chief Scientific Officer | Leadership |
Andrew Bertera | Executive Director of Marketing & Sales | Leadership |
Carole Keating | Executive Director, International Business | Leadership |
Brian Tinger | Director Of Finance | Leadership |
Nicole M. Nichols | Executive Director, Applications & Product Development | Leadership |
Timothy Wong | General Manager, China | Leadership |
Thomas Möellenkamp | General Manager, GmbH | Leadership |
Hiroshi Toshishige | General Manager, Japan | Leadership |
Sue Yap | General Manager,Singapore | Leadership |
Kit Krishnan | Associate Director, NGS | Leadership |
Jennifer Ong | Scientific Director | Leadership |
85 more people are available in the full profile.
Complete people profiles for New England Biolabs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by New England Biolabs
New England Biolabs has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fluorogenics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Lyophilized reagents for stable nucleic acid amplification are supplied. | fluorogenics.co.uk | Salisbury, United Kingdom | 2011 | May 2021 | •••• |
Complete acquisition details for New England Biolabs
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of New England Biolabs
4 dated milestones of New England Biolabs across 51 years, from founding to its latest funding, stage changes and deals.
- Founded New England Biolabs is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Grant, of $11K.
- Acquisition Acquires Fluorogenics.
Web traffic of New England Biolabs
The website of New England Biolabs (neb.com) receives about 749.5K visits a month and ranks #69,042 among all websites worldwide, #4,323 in Biology.
- Monthly visits749.5K
▲ 5.5% vs previous month
- Unique visitors264.8K
per month
- Global rank#69,042
among all websites
- Category rank#4,323
Science and Education · Biology
- Bounce rate45%
- Pages per visit3.3
- Average visit2 min 53 sec
- DevicesDesktop 67% · Mobile 33%
Websites whose visitors overlap most with New England Biolabs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| qiagen.com | 100% | 458.2K | #105,023 | View details | |
| bio-rad.com | 91% | 665.2K | #79,666 | View details | |
| cellsignal.com | 90% | 488.2K | #114,694 | View details | |
promega.com | promega.com | 90% | #192,389 | – | |
| rndsystems.com | 85% | 349K | #159,292 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for New England Biolabs
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as New England Biolabs (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about New England Biolabs
Complete news archive for New England Biolabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about New England Biolabs
New England Biolabs was founded in 1970 and raised its 1st funding round 24 years after it was founded.
New England Biolabs is headquartered in Ipswich, United Kingdom.
James Ellard is the CEO of New England Biolabs, as recorded in our data.
New England Biolabs has 50 employees.
Founded in 1970, New England Biolabs operates in the molecular biology sector from Ipswich, United Kingdom. Discovery, development, and commercialization of reagents and kits are focused on genetic engineering, synthetic biology, and genomics. Over 200 recombinant and 30 native restriction enzymes, along with nicking enzymes and DNA methylases, form the core portfolio. Research and development in these areas are supported globally.
New England Biolabs has made 1 acquisition, including Fluorogenics.
New England Biolabs has 4 investors. Key investors include HHS, Massachusetts Life Sciences Center, NIH SBIR/STTR, and National Science Foundation.
New England Biolabs operates through N.E.B. Ltd.
Yes. New England Biolabs publishes NEB Tools.
The website of New England Biolabs receives about 749 thousand visits a month and ranks #69,042 among all websites worldwide.